| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|
Ascierto, Paolo A
|
|
|
21 |
11 |
p. 1465-1477
|
artikel
|
| 2 |
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
|
Prat, Aleix
|
|
|
21 |
11 |
p. 1455-1464
|
artikel
|
| 3 |
Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age
|
Kunz, Pamela L
|
|
|
21 |
11 |
p. 1395-1397
|
artikel
|
| 4 |
An imbalance in competing mortality favouring Debio 1143
|
Zakeri, Kaveh
|
|
|
21 |
11 |
p. e502
|
artikel
|
| 5 |
An imbalance in competing mortality favouring Debio 1143 – Authors' reply
|
Bourhis, Jean
|
|
|
21 |
11 |
p. e503
|
artikel
|
| 6 |
A roadmap for the early detection and diagnosis of cancer
|
Crosby, David
|
|
|
21 |
11 |
p. 1397-1399
|
artikel
|
| 7 |
Burnout among cancer professionals during COVID-19
|
Burki, Talha Khan
|
|
|
21 |
11 |
p. 1402
|
artikel
|
| 8 |
Cancer and climate change
|
Hiatt, Robert A
|
|
|
21 |
11 |
p. e519-e527
|
artikel
|
| 9 |
Carcinogenicity of opium consumption
|
|
|
|
21 |
11 |
p. 1407-1408
|
artikel
|
| 10 |
Comprehensive guidance on the diagnosis and management of primary mesenchymal tumours of the thyroid gland
|
Gubbi, Sriram
|
|
|
21 |
11 |
p. e528-e537
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 1370–85
|
|
|
|
21 |
11 |
p. e518
|
artikel
|
| 12 |
Correction to Lancet Oncol 2017; 18: 347–56
|
|
|
|
21 |
11 |
p. e518
|
artikel
|
| 13 |
Correction to Lancet Oncol 2020; 21: 1378–86
|
|
|
|
21 |
11 |
p. e518
|
artikel
|
| 14 |
Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer
|
van Golen, Rowan F
|
|
|
21 |
11 |
p. e515
|
artikel
|
| 15 |
Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer – Authors' reply
|
Subbiah, Vivek
|
|
|
21 |
11 |
p. e516
|
artikel
|
| 16 |
Declines in health insurance among cancer survivors since the 2016 US elections
|
Moss, Haley A
|
|
|
21 |
11 |
p. e517
|
artikel
|
| 17 |
ESMO Virtual Congress 2020
|
Gourd, Katherine
|
|
|
21 |
11 |
p. 1403-1404
|
artikel
|
| 18 |
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma
|
Groisberg, Roman
|
|
|
21 |
11 |
p. 1388-1390
|
artikel
|
| 19 |
Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis
|
Parker, Tariq
|
|
|
21 |
11 |
p. 1526-1536
|
artikel
|
| 20 |
HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer
|
Hurvitz, Sara A
|
|
|
21 |
11 |
p. 1392-1393
|
artikel
|
| 21 |
How current assay approval policies are leading to unintended imprecision medicine
|
Salgado, Roberto
|
|
|
21 |
11 |
p. 1399-1401
|
artikel
|
| 22 |
Implementing preoperative endocrine therapy in breast cancer
|
Muñoz, Montserrat
|
|
|
21 |
11 |
p. 1390-1392
|
artikel
|
| 23 |
India–China border standoff raises concerns on drug supplies
|
Sharma, Dinesh C
|
|
|
21 |
11 |
p. 1408-1409
|
artikel
|
| 24 |
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
|
Guo, Christina
|
|
|
21 |
11 |
p. 1478-1488
|
artikel
|
| 25 |
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
|
Smith, Ian
|
|
|
21 |
11 |
p. 1443-1454
|
artikel
|
| 26 |
Mammography screening for breast cancer—the UK Age trial
|
Gera, Ritika
|
|
|
21 |
11 |
p. e507
|
artikel
|
| 27 |
Mammography screening for breast cancer—the UK Age trial
|
Narod, Steven A
|
|
|
21 |
11 |
p. e508
|
artikel
|
| 28 |
Mammography screening for breast cancer—the UK Age trial
|
Al-Shamsi, Humaid O
|
|
|
21 |
11 |
p. e505
|
artikel
|
| 29 |
Mammography screening for breast cancer—the UK Age trial
|
Bell, Katy J L
|
|
|
21 |
11 |
p. e504
|
artikel
|
| 30 |
Mammography screening for breast cancer—the UK Age trial
|
Jatoi, Ismail
|
|
|
21 |
11 |
p. e506
|
artikel
|
| 31 |
Mammography screening for breast cancer—the UK Age trial
|
Donzelli, Alberto
|
|
|
21 |
11 |
p. e509
|
artikel
|
| 32 |
Mammography screening for breast cancer—the UK Age trial – Authors' reply
|
Duffy, Stephen W
|
|
|
21 |
11 |
p. e510
|
artikel
|
| 33 |
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
|
Provencio, Mariano
|
|
|
21 |
11 |
p. 1413-1422
|
artikel
|
| 34 |
New empowerment tool for all patients with cancer in Europe
|
Gourd, Elizabeth
|
|
|
21 |
11 |
p. 1405
|
artikel
|
| 35 |
Ocular surface squamous neoplasia in association with Crohn's disease
|
Tripathy, Devjyoti
|
|
|
21 |
11 |
p. e538
|
artikel
|
| 36 |
Personal choice in The Farewell and Ordinary Love
|
Davis, Sophia
|
|
|
21 |
11 |
p. 1412
|
artikel
|
| 37 |
Prof Theodor Billroth and Ferdinand II King Consort of Portugal: who owns the truth?
|
Szostakowski, Bartlomiej
|
|
|
21 |
11 |
p. 1410-1411
|
artikel
|
| 38 |
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
|
Fizazi, Karim
|
|
|
21 |
11 |
p. 1513-1525
|
artikel
|
| 39 |
Recommendations for breast cancer screening
|
Tabár, László
|
|
|
21 |
11 |
p. e511
|
artikel
|
| 40 |
Recommendations for breast cancer screening
|
Kopans, Daniel B
|
|
|
21 |
11 |
p. e513
|
artikel
|
| 41 |
Recommendations for breast cancer screening
|
Yaffe, Martin J
|
|
|
21 |
11 |
p. e512
|
artikel
|
| 42 |
Recommendations for breast cancer screening – Author's reply
|
Miller, Anthony B
|
|
|
21 |
11 |
p. 514
|
artikel
|
| 43 |
Residual disease after mastectomy
|
Wu, Zhen-Yu
|
|
|
21 |
11 |
p. e500
|
artikel
|
| 44 |
Residual disease after mastectomy
|
Bundred, Nigel J
|
|
|
21 |
11 |
p. e499
|
artikel
|
| 45 |
Residual disease after mastectomy – Authors' reply
|
Kaidar-Person, Orit
|
|
|
21 |
11 |
p. e501
|
artikel
|
| 46 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial
|
Patel, Swapnil
|
|
|
21 |
11 |
p. e497
|
artikel
|
| 47 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial
|
Tanis, Pieter J
|
|
|
21 |
11 |
p. e496
|
artikel
|
| 48 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial – Authors' reply
|
Goéré, Diane
|
|
|
21 |
11 |
p. e498
|
artikel
|
| 49 |
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
|
Xu, Jianming
|
|
|
21 |
11 |
p. 1500-1512
|
artikel
|
| 50 |
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
|
Xu, Jianming
|
|
|
21 |
11 |
p. 1489-1499
|
artikel
|
| 51 |
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
|
Morschhauser, Franck
|
|
|
21 |
11 |
p. 1433-1442
|
artikel
|
| 52 |
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
|
Gounder, Mrinal
|
|
|
21 |
11 |
p. 1423-1432
|
artikel
|
| 53 |
The current state of adjuvant therapy of melanoma
|
Tarhini, Ahmad A
|
|
|
21 |
11 |
p. 1394-1395
|
artikel
|
| 54 |
Tobacco Transformation Index under fire
|
Burki, Talha Khan
|
|
|
21 |
11 |
p. 1406
|
artikel
|
| 55 |
UK cancer care threatened by government incompetence
|
The Lancet Oncology,
|
|
|
21 |
11 |
p. 1387
|
artikel
|
Tijdschrift beschrijving